Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 38

Sort by

Sort Order Select

Journal Articles

Elranatamab, a BCMA Targeted T-Cell Engaging Bispecific Antibody, Induces Durable Clinical and Molecular Responses for Patients with Relapsed or Refractory Multiple Myeloma

Noopur Raje, Nizar Jacques Bahlis, Caitlin Costello, Bhagirathbhai Dholaria, Melhem Solh, Moshe Yair Levy, Michael H Tomasson, Michael A. Damore, Sibo Jiang, Cynthia Basu, Athanasia Skoura, Edward M Chan, Suzanne Trudel, Andrzej Jakubowiak, Michael P Chu, Cristina J. Gasparetto, Andrew P. Dalovisio, Michael Sebag, Alexander M Lesokhin

Blood (2022) 140 (Supplement 1): 388–390.

https://doi.org/10.1182/blood-2022-166494

Published: 2022

Journal Articles

Outcomes of Second-Line (2L) Triplet+ Regimens in Patients with Relapsed/Refractory Multiple Myeloma (MM) Following Progression after First-Line (1L) Lenalidomide in the Connect® MM Disease Registry

Hans C. Lee, Rafat Abonour, Sikander Ailawadhi, Brian G.M. Durie, Cristina J. Gasparetto, James W. Hardin, Mohit Narang, James Omel, Robert M. Rifkin, Howard Terebelo, Kathleen Toomey, Lynne I. Wagner, Samantha Slaff, Dailan Danforth, Weiyuan Chung, Jasmeet Anand, Edward Yu, Derek Tang, Sundar Jagannath

Blood (2022) 140 (Supplement 1): 13256–13258.

https://doi.org/10.1182/blood-2022-158197

Published: 2022

Journal Articles

Impact of COVID-19 on Treatment Patterns and Management of Multiple Myeloma: Insights from the Connect® MM Registry

Joshua Richter, Sikander Ailawadhi, Hans C. Lee, James W. Hardin, Howard R. Terebelo, Rafat Abonour, Lynne I. Wagner, Brian G.M. Durie, James L. Omel, Mohit Narang, Kathleen Toomey, Robert M. Rifkin, Cristina J. Gasparetto, Edward Yu, Jasmeet Anand, Liang Liu, Ying-Ming Jou, Sundar Jagannath

Blood (2022) 140 (Supplement 1): 8089–8091.

https://doi.org/10.1182/blood-2022-158627

Published: 2022

Journal Articles

Multivariable Analyses of Prognostic Factors for Progression-Free Survival (PFS) and Complete Response (CR) with Lenalidomide, Bortezomib, and Dexamethasone (RVd) Alone Versus Rvd Plus Autologous Stem Cell Transplantation (ASCT) in Patients (Pts) with Newly Diagnosed Multiple Myeloma (NDMM) in the Determination Phase 3 Trial

Blood (2022) 140 (Supplement 1): 4834–4838.

https://doi.org/10.1182/blood-2022-162741

Published: 2022

Journal Articles

Once Weekly Oral Selinexor, Pomalidomide, and Dexamethasone in Relapsed Refractory Multiple Myeloma

Blood (2021) 138 (Supplement 1): 2748.

https://doi.org/10.1182/blood-2021-148759

Published: 2021

Journal Articles

Final Overall Survival Results from BELLINI, a Phase 3 Study of Venetoclax or Placebo in Combination with Bortezomib and Dexamethasone in Relapsed/Refractory Multiple Myeloma

Shaji Kumar, Simon J Harrison, Michele Cavo, Javier de la Rubia, Rakesh Popat, Cristina J. Gasparetto, Vania Hungria, Hans Salwender, Kenshi Suzuki, Inho Kim, Maika Onishi, Grace Ku, Rajvineeth Kumar Pothacamury, Vasudha Sehgal, Abdullah A. Masud, Jeremy A. Ross, Edyta Dobkowska, Philippe Moreau

Blood (2021) 138 (Supplement 1): 84.

https://doi.org/10.1182/blood-2021-145757

Published: 2021

Journal Articles

Efficacy and Safety of Selinexor-Containing Regimens in Patients with Multiple Myeloma Previously Treated with Anti-CD38 Monoclonal Antibodies (αCD38 mAb)

Blood (2021) 138 (Supplement 1): 1651.

https://doi.org/10.1182/blood-2021-150232

Published: 2021

Journal Articles

Real World Observational Study Using Clonoseq® Next Generation Sequencing in Hematologic Malignancies: The 'Watch' Registry

Krish Patel, MD, Neil Bailey, MSc, Cristina J. Gasparetto, MD, Tomer Mark, MD MSc, Bijal Shah, MD, Jakub Svoboda, MD, Michael A. Thompson, MD PhD, Heidi Simmons, PhD, Mark Schliekelman, PhD, Allison P. Jacob, Lance Baldo, MD, John M. Pagel, MDPhD

Blood (2020) 136 (Supplement 1): 37.

https://doi.org/10.1182/blood-2020-141440

Published: 2020

Journal Articles

Clinical Features and Survival Outcomes in Diabetic Patients with Newly Diagnosed Multiple Myeloma (NDMM) Enrolled in the Connect ® MM Registry

Lisa La, Sundar Jagannath, MD, Sikander Ailawadhi, Brian G.M. Durie, MD, Cristina J. Gasparetto, MD, James W. Hardin, PhD, Hans C. Lee, MD, Mohit Narang, MD, James L. Omel, MD, Robert M. Rifkin, MD, Howard R. Terebelo, DO, Kathleen Toomey, MD, Lynne I. Wagner, PhD, Mazaher Dhalla, PharmD, Liang Liu, MS, Ling Yang, MS, Prashant Joshi, MD, Rafat Abonour, MD

Blood (2020) 136 (Supplement 1): 49–50.

https://doi.org/10.1182/blood-2020-137309

Published: 2020

Journal Articles

A Phase I, Open-Label Study to Evaluate the Safety, Pharmacokinetic, Pharmacodynamic, and Clinical Activity of PF-06863135, a B-Cell Maturation Antigen/CD3 Bispecific Antibody, in Patients with Relapsed/Refractory Advanced Multiple Myeloma

Alexander M. Lesokhin, MD, Noopur Raje, MD, Cristina J Gasparetto, MD, Justine Walker, MD, Heike I. Krupka, PhD PMP, Tenshang Joh, PhD, Carrie T. Taylor, PhD MHS, Andrzej Jakubowiak, MD PhD

Blood (2018) 132 (Supplement 1): 3229.

https://doi.org/10.1182/blood-2018-99-110427

Published: 2018

Journal Articles

Treatment Choices and Outcomes for Patients with Multiple Myeloma after Relapse on Lenalidomide Maintenance Therapy: Results from the Connect ® MM Registry

Sundar Jagannath, MD, Mohit Narang, MD, Sikander Ailawadhi, Robert M Rifkin, MD, Howard R Terebelo, DO, Kathleen Toomey, MD, Brian GM Durie, MD, James W Hardin, PhD, Cristina J Gasparetto, MD, Lynne Wagner, PhD, James Omel, MD, Shankar Srinivasan, PhD MBA, Amani Kitali, MPH, MBA, Amit Agarwal, MD PhD, Rafat Abonour, MD

Blood (2018) 132 (Supplement 1): 3232.

https://doi.org/10.1182/blood-2018-99-110877

Published: 2018

Journal Articles

Deep and Durable Responses with Selinexor, Daratumumab, and Dexamethasome (SDd) in Patients with Multiple Myeloma (MM) Previously Exposed to Proteasome Inhibitors and Immunomodulatory Drugs: Results of Phase 1b Study of SDd

Blood (2018) 132 (Supplement 1): 599.

https://doi.org/10.1182/blood-2018-99-117201

Published: 2018

Journal Articles

Selinexor Plus Pomalidomide and Low Dose Dexamethasone (SPd) in Patients with Relapsed or Refractory Multiple Myeloma

Christine I Chen, MD, Heather J. Sutherland, MD PhD, Rami Kotb, MD, Michael Sebag, MD PhD, Darrell J. White, MD, William Bensinger, MD, Cristina J Gasparetto, MD, Richard Leblanc, MDFRCPC, Christopher P. Venner, MD FRCPC, Suzanne Lentzsch, MD, Gary J. Schiller, MD, Brea Lipe, MD, Aldo Del Col, Jatin J. Shah, MD, Jacqueline Jeha, Jean-Richard Saint-Martin, Michael G. Kauffman, MD PhD, Sharon Shacham, PhD MBA, Nizar Bahlis, MD

Blood (2018) 132 (Supplement 1): 1993.

https://doi.org/10.1182/blood-2018-99-117349

Published: 2018

Journal Articles

Results from a Phase II Study of Isatuximab As a Single Agent and in Combination with Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma

Meletios A Dimopoulos, MD, Sara Bringhen, MD, Pekka Anttila, MD, Marcelo Capra, MD PhD, Michele Cavo, MD, Craig E. Cole, MD, Cristina J Gasparetto, MD, Vania T. M. Hungria, MD PhD, Matthew Jenner, Vladimir Vorobyev, MD PhD, Eduardo Yanez Ruiz, Jianyun Yin, Anthony Hamlett, Ravi Vij, MBBS

Blood (2018) 132 (Supplement 1): 155.

https://doi.org/10.1182/blood-2018-155

Published: 2018

Journal Articles

Baseline Disease Characteristics and Diagnostic Patterns for NDMM of the Connect ® MM Registry: Observations over Time in Cohort 1 (2009-2011) and Cohort 2 (2012-2016)

Mohit Narang, MD, Rafat Abonour, MD, Brian G. M. Durie, MD, Cristina J. Gasparetto, MD, Kathleen Toomey, MD, James W. Hardin, PhD, Sundar Jagannath, MD, Howard R. Terebelo, DO, Lynne Wagner, PhD, Shankar Srinivasan, PhD, E. Dawn Flick, MPH. ScD, Faiza Zafar, MPAS, Amani Kitali, MBA, MPH, Amit Agarwal, MD PhD, Robert M Rifkin, MD

Blood (2017) 130 (Supplement 1): 3156.

https://doi.org/10.1182/blood.V130.Suppl_1.3156.3156

Published: 2017

Journal Articles

A Phase Ib/II Trial of Selinexor Combined with Lenalidomide and Low Dose Dexamethasone in Patients with Relapsed / Refractory Multiple Myeloma

Darrell J White, MD, Nizar J. Bahlis, MD, Christopher P. Venner, MD, Gary J Schiller, MD, Cristina J. Gasparetto, MD, Heather J. Sutherland, MD PhD FRCPC, Michael Sebag, MD PhD, Suzanne Lentzsch, MD PhD, Rami Kotb, MD, William Bensinger, MD, Brea C. Lipe, MD, Christine I Chen, MD FRCP(C), Aldo Del Col, BSPharm, MBA, Michael G. Kauffman, MD PhD, Sharon Shacham, PhD MBA, Jacqueline Jeha, Jean-Richard Saint-Martin, Jatin Shah, MD, Richard LeBlanc, MDFRCPC

Blood (2017) 130 (Supplement 1): 1861.

https://doi.org/10.1182/blood.V130.Suppl_1.1861.1861

Published: 2017

Journal Articles

Revised-International Staging System (R-ISS) Is Independently Predictive and Prognostic for Early Relapse (<24 months) after Upfront Autologous Hematopoietic Cell Transplantation (AHCT) for Newly Diagnosed Multiple Myeloma (MM

Sathish Kumar, Anita D'Souza, MBBS, Emma C. Scott, MD, Raphael Fraser, Omar Davila, Cristina J. Gasparetto, MD, Shaji K Kumar, MD, Tomer M Mark, MDMSc, Yago Nieto, MD PhD, Parameswaran Hari, MD MRCP, MS

Blood (2017) 130 (Supplement 1): 2024.

https://doi.org/10.1182/blood.V130.Suppl_1.2024.2024

Published: 2017

Journal Articles

Hematopoietic Stem Cell Transplantation at Home

Anthony D. Sung, MD, Krista R. Nichols, RN, MSN, AOCNS, Julia A. Messina, MD, Kristi Romero, BA, Tara Dalton, MBS, Amy Bush, BA, Megan Covington, BS, Rebecca Shelby, PhD, Jennifer Frith, RN, MSN, OCN, Cristina J. Gasparetto, MD, Mitchell E. Horwitz, MD, Gwynn D. Long, MD, Richard Lopez, MD, David A. Rizzieri, MD, Stefanie Sarantopoulos, MD PhD, Keith M. Sullivan, MD, Nelson J. Chao, MDM.B.A

Blood (2017) 130 (Supplement 1): 745.

https://doi.org/10.1182/blood.V130.Suppl_1.745.745

Published: 2017

Journal Articles

A Phase 1b Study to Assess the Combination of Selinexor and Daratumumab in Patients with Relapsed / Refractory Multiple Myeloma Previously Exposed to Proteasome Inhibitors (PI) and Immunomodulatory Drugs (IMiDs)

Cristina J. Gasparetto, MD, Suzanne Lentzsch, MD PhD, Gary J Schiller, MD, William Bensinger, MD, Nizar J. Bahlis, MD, Heather J. Sutherland, MD PhD FRCPC, Darrell J White, MD, Michael Sebag, MD PhD, Rami Kotb, MD, Christopher P. Venner, MD, Richard LeBlanc, MDFRCPC, Christine I Chen, MD FRCP(C), Aldo Del Col, BSPharm, MBA, Michael G. Kauffman, MD PhD, Sharon Shacham, PhD MBA, Jacqueline Jeha, Jean-Richard Saint-Martin, Jatin Shah, MD, Brea C. Lipe, MD

Blood (2017) 130 (Supplement 1): 3100.

https://doi.org/10.1182/blood.V130.Suppl_1.3100.3100

Published: 2017

Journal Articles

Differential Effect of t(11;14) Abnormality on Survival and Depth of Response in African American (AA) and Non-AA (NAA) Patients (Pts) with Newly Diagnosed Multiple Myeloma (NDMM) in the Connect ® MM Registry

Cristina J. Gasparetto, MD, Rafat Abonour, MD, Sundar Jagannath, MD, Brian G. M. Durie, MD, Mohit Narang, MD, Howard R. Terebelo, DO, Kathleen Toomey, MD, James W. Hardin, PhD, Lynne Wagner, PhD, Shankar Srinivasan, PhD, Amani Kitali, MBA, MPH, E. Dawn Flick, MPH, Faiza Zafar, MPAS, Amit Agarwal, MD PhD, Robert M Rifkin, MD

Blood (2017) 130 (Supplement 1): 3101.

https://doi.org/10.1182/blood.V130.Suppl_1.3101.3101

Published: 2017

NARROW

Elranatamab, a BCMA Targeted T-Cell Engaging Bispecific Antibody, Induces Durable Clinical and Molecular Responses for Patients with Relapsed or Refractory Multiple Myeloma

Outcomes of Second-Line (2L) Triplet+ Regimens in Patients with Relapsed/Refractory Multiple Myeloma (MM) Following Progression after First-Line (1L) Lenalidomide in the Connect® MM Disease Registry

Impact of COVID-19 on Treatment Patterns and Management of Multiple Myeloma: Insights from the Connect® MM Registry

Once Weekly Oral Selinexor, Pomalidomide, and Dexamethasone in Relapsed Refractory Multiple Myeloma

Final Overall Survival Results from BELLINI, a Phase 3 Study of Venetoclax or Placebo in Combination with Bortezomib and Dexamethasone in Relapsed/Refractory Multiple Myeloma

Efficacy and Safety of Selinexor-Containing Regimens in Patients with Multiple Myeloma Previously Treated with Anti-CD38 Monoclonal Antibodies (αCD38 mAb)

Real World Observational Study Using Clonoseq® Next Generation Sequencing in Hematologic Malignancies: The 'Watch' Registry

Clinical Features and Survival Outcomes in Diabetic Patients with Newly Diagnosed Multiple Myeloma (NDMM) Enrolled in the Connect ® MM Registry

A Phase I, Open-Label Study to Evaluate the Safety, Pharmacokinetic, Pharmacodynamic, and Clinical Activity of PF-06863135, a B-Cell Maturation Antigen/CD3 Bispecific Antibody, in Patients with Relapsed/Refractory Advanced Multiple Myeloma

Treatment Choices and Outcomes for Patients with Multiple Myeloma after Relapse on Lenalidomide Maintenance Therapy: Results from the Connect ® MM Registry

Deep and Durable Responses with Selinexor, Daratumumab, and Dexamethasome (SDd) in Patients with Multiple Myeloma (MM) Previously Exposed to Proteasome Inhibitors and Immunomodulatory Drugs: Results of Phase 1b Study of SDd

Selinexor Plus Pomalidomide and Low Dose Dexamethasone (SPd) in Patients with Relapsed or Refractory Multiple Myeloma

Results from a Phase II Study of Isatuximab As a Single Agent and in Combination with Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma

Baseline Disease Characteristics and Diagnostic Patterns for NDMM of the Connect ® MM Registry: Observations over Time in Cohort 1 (2009-2011) and Cohort 2 (2012-2016)

A Phase Ib/II Trial of Selinexor Combined with Lenalidomide and Low Dose Dexamethasone in Patients with Relapsed / Refractory Multiple Myeloma

Revised-International Staging System (R-ISS) Is Independently Predictive and Prognostic for Early Relapse (<24 months) after Upfront Autologous Hematopoietic Cell Transplantation (AHCT) for Newly Diagnosed Multiple Myeloma (MM

Hematopoietic Stem Cell Transplantation at Home

A Phase 1b Study to Assess the Combination of Selinexor and Daratumumab in Patients with Relapsed / Refractory Multiple Myeloma Previously Exposed to Proteasome Inhibitors (PI) and Immunomodulatory Drugs (IMiDs)

Differential Effect of t(11;14) Abnormality on Survival and Depth of Response in African American (AA) and Non-AA (NAA) Patients (Pts) with Newly Diagnosed Multiple Myeloma (NDMM) in the Connect ® MM Registry

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only